Compare SW & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SW | BIIB |
|---|---|---|
| Founded | 1934 | 1978 |
| Country | Ireland | United States |
| Employees | 97000 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.3B | 27.1B |
| IPO Year | N/A | 1996 |
| Metric | SW | BIIB |
|---|---|---|
| Price | $39.34 | $175.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 28 |
| Target Price | $54.08 | ★ $197.46 |
| AVG Volume (30 Days) | ★ 5.3M | 919.0K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 8.79 |
| Revenue | N/A | ★ $9,890,600,000.00 |
| Revenue This Year | $4.53 | N/A |
| Revenue Next Year | $2.94 | N/A |
| P/E Ratio | $38.98 | ★ $19.57 |
| Revenue Growth | N/A | ★ 2.22 |
| 52 Week Low | $32.73 | $110.04 |
| 52 Week High | $52.65 | $202.41 |
| Indicator | SW | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 44.37 | 40.57 |
| Support Level | $36.00 | $170.99 |
| Resistance Level | $44.38 | $188.76 |
| Average True Range (ATR) | 1.40 | 5.40 |
| MACD | 0.24 | -1.25 |
| Stochastic Oscillator | 67.46 | 26.74 |
Smurfit WestRock PLC manufactures corrugated packaging and consumer packaging, such as folding cartons and paperboard. operates a vertically integrated system supplying wood and recovered fiber to produce various grades of board, which are then converted into packaging products. Its main packaging categories include corrugated containers and consumer packaging, with additional products such as solidboard, kraft paper, graphic board, paper sacks, and bag-in-box packaging. The company's geographical segments include North America (including the U.S., Canada and Mexico), Europe, the Middle East and Africa and Asia-Pacific, and Latin America. The majority of the company's revenue is derived from product sales in the North American region.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).